Research Areas

A 4-Week Randomized, Multicenter, Double-blind, Placebo-and Active-controlled, Parallel Group, Forced-titration Phase IIB Study Comparing the Efficacy and Safety of Ascending Doses of an investigational medication and Oxycodone Prolonged release up to 20 mg BID to Placebo in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthrits of the Knee

A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of A Novel Investigational Medication in Subjects with Osteoarthritis of the Knee

A Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Safety and Efficacy of An Investigational Medication in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of an investigational medication in the Treatment of Obese, Type 2 Diabetic Subjects Managed with Diet or Metformin.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an investigational medication in Obese Patients

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of A Novel Investigational Medication in Obese Patients

A Randomized, Double-Blind Placebo-Controlled, Flexible Dose Study of the efficacy and Safety of an Investigational Medication in Comparison to Gabapentin In Patients With Painful Diabetic Neuropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study of the Efficacy and Safety of an investigational medication in Patients With Diabetic Sensorimotor Polyneuropathy

A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of An Investigational Medication For Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of An Investigational Medication in Patients With Painful Diabetic Neuropathy

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of An Investigational Medication in Subjects with Painful Diabetic Peripheral Neuropathy

A Phase II Randomized, Double Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety and Effectiveness of An Investigational Medication in the Treatment of Subjects with Diabetic Neuropathy

Phase III, Open-Label Study of the Safety and Efficacy of An Oral Investigational Medication in Hypogonadal Men

A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of an Investigational Medication Versus Rosuvastatin in Patients With Primary Hypercholesterolemia

Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of an investigational medication Compared to Placebo. Part B: A Dose-Ranging Study to Evaluate the Tolerability of an Investigational Medication and its Effects on Niacin-Induced Flushing in Lipid Clinic Patients.

A Phase 3, double-blind, placebo-controlled, randomized, parallel group, multicenter study of the efficacy, safety and tolerability of an investigational medication administered orally, once daily for 24 weeks, compared to atorvastatin alone or placebo, in subjects with Frederickson Type IIa dyslipidemia.

A Study to Evaluate the Efficacy and Safety of an Investigational Medication Coadministration in Patients With Mixed Hyperlipidemia

A Double-Blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety and Efficacy of An Investigational Medication in Subjects With a 10 Year Framingham Risk Score of 10% or Less and Currently Not Receiving Prescription Lipid-lowering Therapy

A Randomized, Double-Blind Study of the Efficacy and Safety of An Investigational Medication Added-on to Atorvastatin versus Ezetimibe Added-on to Atorvastatin versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Long-Term Safety and Tolerability of An Investigational Medication in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events